Treatment of new-onset type 1 diabetes with peptide DiaPep277® is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial
Article first published online: 24 NOV 2006
Copyright © 2006 John Wiley & Sons, Ltd.
Diabetes/Metabolism Research and Reviews
Volume 23, Issue 4, pages 292–298, May/June 2007
How to Cite
Raz, I., Avron, A., Tamir, M., Metzger, M., Symer, L., Eldor, R., Cohen, I. R. and Elias, D. (2007), Treatment of new-onset type 1 diabetes with peptide DiaPep277® is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phase II trial. Diabetes Metab. Res. Rev., 23: 292–298. doi: 10.1002/dmrr.712
- Issue published online: 2 MAY 2007
- Article first published online: 24 NOV 2006
- Manuscript Accepted: 12 OCT 2006
- Manuscript Revised: 30 AUG 2006
- Manuscript Received: 11 APR 2006
- type 1 diabetes;
- randomized controlled trial;
Treatment with DiaPep277®, a peptide derived from HSP60, has been shown to preserve beta-cell function in non-obese diabetic mouse (NOD) mice and in a trial with newly diagnosed human patients with type 1 diabetes treated over a 10-month period. This article extends the clinical trial observations to a total of 20 months of treatment to determine the safety and the effects of repeated doses of DiaPep277 on endogenous insulin secretion, metabolic control, and exogenous insulin requirements.
Thirty-five male patients (aged 16–58) with a basal C-peptide greater than 0.1 nmol/L were assigned to periodic treatment with DiaPep277 (1 mg) or placebo for a 12-month treatment and 18-month observation protocol, later extended to an additional year of treatment. Stimulated C-peptide, HbA1c, and an exogenous insulin dose were the clinical endpoints.
At 18 months, stimulated C-peptide concentrations had fallen in the placebo group (p = 0.0005) but were maintained in the DiaPep277 group. The need for exogenous insulin was higher in the placebo group than in the DiaPep277 group. Mean HbA1c concentrations were similar in both groups. After extension of the study, patients continuing treatment with DiaPep277 and those switched from placebo to DiaPep277 manifested a trend towards a greater preservation of beta-cell function compared to patients maintained on or switched to placebo. The safety profile of DiaPep277 was similar between the treatment and placebo groups, and no drug-related adverse events occurred.
Periodic treatment of subjects with DiaPep277 over 2 years was safe and associated preservation of endogenous insulin secretion up to 18 months was observed. Copyright © 2007 John Wiley & Sons, Ltd.